Fostering a multidisciplinary approach to HIV vaccine development

With 37 million people living with HIV worldwide, and over 2 million new infections diagnosed each year, an effective vaccine is regarded as the most potent public health strategy for addressing the pandemic.  Despite the many advances in the understanding, treatment and prevention of HIV made over the past 30 years, the development of broadly-effective HIV vaccine has remained unachievable.

The European HIV Alliance (EHVA) is a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. The international alliance, which includes academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America, will work to discover and progress novel vaccine candidates through the clinic.

EHVA Press Release    > Project FactSheet (PDF)      > About us (PDF)


  • EHVA initiates a clinical trial to test a novel therapeutic vaccine and immunotherapy drug

    The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland.

    Press release

  • Next Consortium Meeting of EHVA June 2018

    Next Consortium Meeting of EHVA will be held 21st & 22nd of June at the School of Medecine, Barcelona

  • 1st December 2018 World Aids Day

Partnering organizations

Drawing from 39 partner organizations, EHVA encompasses expertise in the fields of molecular biology, structural biology, vectorology, adjuvants delivery, immunology, clinical science and biostatics. The alliance is devised to approach the challenges that have hindered the development of a broadly effective vaccine, to date, from all possible angles.

The multidisciplinary-partnership alliance was initiated by Professor Yves Levy of the French Institute of Health (INSERM) and Professor Giuseppe Pantaleo of the Swiss Vaccine Research Institute...


EHVA goals

EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.

EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032